P. 1
Lundberg

Lundberg

|Views: 6|Likes:
Published by indrashis2010

More info:

Published by: indrashis2010 on Jun 26, 2012
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

08/22/2014

pdf

text

original

Based on the information in the database you could show some interesting statistics regarding the
biomedical industry in Sweden. Since the database doesn’t have integrity regarding all biomedical
companies in Sweden the following example data does not give a complete and valid picture of the
situation in Sweden. Instead it gives you information about the companies that are stored in the
database. The reason for executing this example is to show the kind analysis that you could make
with the database if you perform a study where you store data about all (or a statistical selection of)
the Swedish biomedical companies.

Focus areas

Of the 182 R&D biotechnology
companies in the database 44 were
registered as working with
immunology/infection, making that
focus area the most frequent in the
database. Second most frequent was
cancer (22 companies) and then
followed bioinformatics (17),
CNS/Pain (17), Cardiovascular (16)
and Genetics (16) (Fig. 28).

When looking at the focusareas for
the most recently formed companies
(1996-2000) the most companies still
work with immunology/infection
(10). Now genetics had moved up to
second (6 companies) and after that
bioinformatics (4), CNS/Pain (4)
(Fig. 29).

Geographic development

The number of companies that
works with R&D in the healthcare
sector (in the database) grew from
18 in 1975 to 180 in 1999. The
expansion has been stable and rapid
during last 15 years. This is though
just a count of the companies and
doesn’t count the growth of the
companies. But at least it shows that

the R&D healthcare sector is growing very fast in Sweden (Fig 30).
The expansion has mainly been in Stockholm. Here number of companies grew from 51 in 1995 to
70 in 2000 compared to 95 in 1995 to 112 in 2000 in the rest of country (Fig. 31).
Of the 36 companies created during the last five years 22 has been formed in the StandUp Region
(Stockholm-Uppsala) (fig. 32).

Fig. 28. Focus areas for R&D biotech companies in Sweden.

Other

Bioinformatics

Cancer

CNS/Pain

Cardio-
vascular

Genetics

Immunology/
Infection

Anestheiology/Intensive Care
Bioinformatics
Cancer

Cardiovascular
Cell and Molecular Biology
CNS/Pain
Ear/Nose/Throat
Endocrinology/Metabolism

Eye
Gastrointestinal
Genetics
Geriatrics

Gynecology/Obstetrics
Immunology/Infection
Kidney/Urology
Lung/Respiration

Nutrition
Odontology
Pathology

Pediatrics
Skin/Woundhealing
Surgery/Orthopedics
Transplantation

Other

Biotech focus areas in Sweden

Biotech focus areas in Sweden

Total: 182 companies

Fig. 29. Focus areas for R&D biotech companies formed in
Sweden between 1996 and 2000 .

0

2

4

6

8

10

12

C

a

r

d

i

o

v

a

s

c

u

l

a

r

E

n

d

o

c

r

i

n

o

l

o

g

y

/

M

e

t

a

b

o

l

i

s

m

G

a

s

t

r

o

i

n

t

e

s

t

i

n

a

l

L

u

n

g

/

R

e

s

p

i

r

a

t

i

o

n

C

a

n

c

e

r

C

e

l

l

a

n

d

M

o

l

e

c

u

l

a

r

B

i

o

l

o

g

y

E

a

r

/

N

o

s

e

/

T

h

r

o

a

t

B

i

o

i

n

f

o

r

m

a

t

i

c

s

C

N

S

/

P

a

i

n

G

e

n

e

t

i

c

s

I

m

m

u

n

o

l

o

g

y

/

I

n

f

e

c

t

i

o

n

Focusarea

Number of new companies

1996-2000

Focusareas for new biocompanies

Focusareas for new biocompanies

42

The figures in this example has shown that there is a rapid development of R&D healthcare
companies in Sweden, mainly in tha StandUp region. The development is mainly taking place with in
the immunology and genetics fields.

Still, as was stated in the beginning of
this example, these calculations are
based on the companies being stored at
present in the databased and are not
the complete picture of the
development in Sweden. It remains for
further studies to make sure that the
database have integrity for these
companies. It will be interesting to see
if it will give the same result as this
preliminary study.

StandUp Region

Lund

Göteborg

Umeå

Umeå
5%

Lund
20%

Göteborg
15%

Uppsala
18%

Stockholm
42%

StandUp
Region
61%

Umeå Lund Göteborg Uppsala Stockholm

Geographic distribution of new biocompanies

Geographic distribution of new biocompanies

Fig. 32. Geographic distribution of R&D Healthcare
companies in Sweden formed between 1996 and 2001

Fig. 31. Geographic development of newly formed R&D
healthcare companies in Sweden between 196 and 2000.

0

10

20

30

40

50

60

70

80

Before
1996

1996

1997 1998

1999 2000

Stockholm

Lund

Göteborg

Uppsala

Umeå

Geographic development 1996

Geographic development 1996--2000
2000

Fig. 30. Total number of companies working with Healthcare
R&D in Sweden.

R&D Life

R&D Life--science companies
science companies
1975

1975--2000
2000

0

20

40

60

80

100

120

140

160

180

Before 1975 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999

Total number of biocompanies

43

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->